• Founded in 2022, ImmunAdd Inc., is a privately held biopharmaceutical company on a mission to improve health through advances in adjuvant design and formulation.
  • We are developing next generation saponin adjuvants and using them as the basis for new combination adjuvants and adjuvanted vaccines.
  • Our lead adjuvant, IA-05, is a rationally designed analogue of the saponin adjuvant QS-21. IA-05 elicits immune responses comparable to or better than QS-21 and is better tolerated and more stable.
  • With IA-05 as the foundation, ImmunAdd is designing adjuvant platforms able to deliver a specific immune response.

We help your vaccine work BETTER 

  • Increase cell-mediated immunity
  • Shape immune response
  • Cross-presenting Immunity
  • Enable immunization in weakened immune system
  • Reduce antigen dose
  • Reduce number of doses
  • Sustainable and Innovation